Barclays PLC Has $640,000 Stock Holdings in Codexis, Inc. (NASDAQ:CDXS)

Barclays PLC lifted its holdings in Codexis, Inc. (NASDAQ:CDXS) by 51.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 207,628 shares of the biotechnology company’s stock after purchasing an additional 70,255 shares during the period. Barclays PLC owned 0.26% of Codexis worth $640,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of CDXS. Los Angeles Capital Management LLC bought a new position in shares of Codexis in the 2nd quarter valued at approximately $54,000. Intech Investment Management LLC acquired a new stake in shares of Codexis in the third quarter worth $66,000. Marshall Wace LLP bought a new stake in shares of Codexis during the 2nd quarter worth $89,000. Algert Global LLC grew its stake in Codexis by 17.1% in the 2nd quarter. Algert Global LLC now owns 41,556 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 6,069 shares during the last quarter. Finally, Squarepoint Ops LLC raised its holdings in Codexis by 113.8% in the 2nd quarter. Squarepoint Ops LLC now owns 74,531 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 39,664 shares during the period. 78.54% of the stock is currently owned by institutional investors.

Codexis Price Performance

NASDAQ:CDXS opened at $4.77 on Thursday. The company has a quick ratio of 3.15, a current ratio of 3.21 and a debt-to-equity ratio of 0.39. The firm has a market cap of $388.17 million, a PE ratio of -5.48 and a beta of 2.15. Codexis, Inc. has a 12 month low of $2.53 and a 12 month high of $6.08. The company’s 50-day moving average price is $4.47 and its two-hundred day moving average price is $3.57.

Codexis (NASDAQ:CDXS) last released its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.04). Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. The business had revenue of $12.83 million for the quarter, compared to the consensus estimate of $11.64 million. During the same quarter last year, the company earned ($0.26) earnings per share. On average, equities analysts anticipate that Codexis, Inc. will post -0.77 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CDXS. Cantor Fitzgerald restated an “overweight” rating and set a $11.00 target price on shares of Codexis in a research note on Friday, November 22nd. Benchmark reissued a “hold” rating on shares of Codexis in a research report on Monday, November 4th.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.